文献速递治疗药物监测与药物基因组学

呼气代谢组学无创估算人体全身药物暴露的转化概念验证研究

Non-Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof-of-Concept Study.
PubMed 文献 · Clin Pharmacol Ther · 2026-08-07

该前瞻性观察研究纳入117名成人,采集127对呼气-血清配对样本,用SESI-HRMS呼气代谢组学估算丙戊酸、左乙拉西坦、拉莫三嗪和拉考沙胺的全身暴露。四种药物呼气估算值与实测血清浓度的 concordance correlation coefficient 为0.733–0.895,支持呼气分析无创估算药物暴露的可行性,但尚不能替代血清治疗药物监测。

要点

  • 呼气代谢组学可无创估算丙戊酸、左乙拉西坦、拉莫三嗪和拉考沙胺的全身药物暴露。
  • 四种药物的呼气估算值与血清浓度的一致性相关系数为0.733–0.895。
  • 拉考沙胺亚组样本量仅n=16,其结果应视为初步发现。

核心结论

  • 呼气分析可用于药理学上不同药物的全身药物暴露无创估算,但目前应视为血清监测的补充手段。
  • 临床实施前尚需外部多中心和纵向验证。

研究设计与样本

  • 前瞻性观察研究,在常规门诊条件下纳入117名成人,采集127对呼气-血清配对测量。
  • 采用基于二次电喷雾电离高分辨质谱(SESI-HRMS)的呼气代谢组学,从一次呼气采样 session 估算全身药物暴露。
  • 模型性能用重复k折交叉验证评估,以一致性相关系数量化。

主要发现

  • 丙戊酸、左乙拉西坦、拉莫三嗪和拉考沙胺的呼气估算值与实测血清浓度呈中度一致性,一致性相关系数为0.733–0.895。
  • 拉考沙胺亚组样本量有限(n=16),其发现应视为初步结果。
  • 先前定义的11特征丙戊酸呼气特征在另一成人队列中保留预测效用,支持其在本分析框架内的跨队列可迁移性。

关键数值与推荐

  • 四种药物呼气估算值与血清浓度的一致性相关系数范围为0.733–0.895。
  • 拉考沙胺亚组样本量n=16。
  • 丙戊酸呼气特征包含11个特征。

临床怎么用

  • 呼气代谢组学目前可作为血清治疗药物监测的补充,不应替代血清监测。
  • 临床常规应用前需完成外部多中心与纵向验证。

局限性

  • 观察到的相关性支持概念验证,但未确立与血清治疗药物监测的临床可互换性。
  • 拉考沙胺亚组样本量有限(n=16),结果仅为初步。
  • 需外部多中心和纵向验证后方可临床实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate assessment of systemic drug exposure in humans remains challenging, as conventional approaches rely on intermittent blood sampling and laboratory-based assays that are invasive and provide limited temporal resolution. Exhaled breath contains volatile and semi-volatile compounds arising from drug metabolism and downstream biological processes, suggesting that it may serve as a non-invasive matrix for integrated pharmacokinetic sensing. We conducted a prospective observational study using exhaled breath metabolomics based on secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS) to estimate systemic drug exposure from a breath-sampling session. A total of 117 adults provided 127 paired breath-serum measurements under routine outpatient conditions. Model performance was evaluated using repeated k-fold cross-validation and quantified using concordance correlation coefficients. Breath-derived estimates of valproic acid, levetiracetam, lamotrigine, and lacosamide showed moderate concordance with measured serum concentrations, with concordance correlation coefficients ranging from 0.733 to 0.895 across medications. The lacosamide findings should be considered preliminary because of the limited subgroup size (n = 16). The observed concordance supports proof-of-concept exposure estimation but does not establish clinical interchangeability with serum-based therapeutic drug monitoring. The previously defined 11-feature VPA breath signature retained predictive utility in a separate adult cohort, supporting its cross-cohort transferability within the present analytical framework. These findings support the feasibility of exhaled breath analysis for non-invasive estimation of systemic drug exposure across pharmacologically distinct medications. Breath analysis should currently be considered complementary to serum-based monitoring, and external multicenter and longitudinal validation is required before clinical implementation.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fricke K, Baur DM, Singh KD, et al. Non-Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof-of-Concept Study. Clin Pharmacol Ther. 2026. PMID: 42568048. doi:10.1002/cpt.70437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。